Coraxan Use in Patients with Cardiovascular and Pulmonary Pathology

Authors

  • Rajabova N.T PhD, Senior Lecturer, Department of Pediatrics and higher nursing, Urgench Branch of TMA, Urgench, Uzbekistan
  • Kilicheva T.A Assistant of the Department of Propaedeutics of pediatric diseases, Urgench Branch of TMA, Urgench, Uzbekistan

Keywords:

Coraxan, ischemic heart disease, blood pressure

Abstract

The article studies the efficacy of the drug Coraxan in the complex therapy of patients with coronary heart disease (CHD) and arterial hypertension (AH) in combination with chronic obstructive pulmonary disease (COPD). The use of Coraxan in the treatment of patients with combined cardiopulmonary pathology leads to a significant decrease in blood pressure (BP) and heart rate (HR), reduction of angina attacks. Coraxan increases tolerance to physical activity (PA).

References

Ражабова, Н. Т., Шамуратова, Г. Б., & Раджапов, А. А. (2019). Исследование действия

карведилола у пациентов с дилатационной кардиомиопатией. Вопросы науки и

образования, (7 (53)), 206-210.Ташкенбаева, Э., & Ражабова, Н. (2023). ВЛИЯНИЕ ЦИТОКИНОВ В РАЗВИТИИ ИБС

У ЖЕНЩИН В ПЕРИОД МЕНОПАУЗЫ. Science and innovation in the education

system, 2(7), 28-29.

Ташкенбаева, Э., Ражабова, Н., & Матязовой, Ф. (2023). РОЛЬ ЦИТОКИНОВ В

РАЗВИТИИ ИБС У ЖЕНЩИН В ПЕРИОД МЕНОПАУЗЫ. Евразийский журнал

академических исследований, 3(6), 90-97.

Downloads

Published

2024-01-30

Issue

Vol. 26 (2024): TPJ

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Coraxan Use in Patients with Cardiovascular and Pulmonary Pathology. (2024). The Peerian Journal, 26, 25-28. https://peerianjournal.com/index.php/tpj/article/view/744